AbCellera Biologics Inc. Investment Income, Interest
AbCellera Biologics Inc. (ABCL) reported Investment Income, Interest of $3.64 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-05-11
- AbCellera Biologics Inc. investment income, interest for the quarter ending 2026-03-31 was $3.64M, a 34.04% decline year-over-year.
- AbCellera Biologics Inc. investment income, interest for the quarter ending 2025-12-31 was $5.92M, a 31.70% decline year-over-year.
- AbCellera Biologics Inc. investment income, interest for the quarter ending 2025-09-30 was $6.76M, a 29.55% decline year-over-year.
- AbCellera Biologics Inc. investment income, interest for the quarter ending 2025-06-30 was $7.59M, a 22.54% decline year-over-year.
- AbCellera Biologics Inc. investment income, interest for fiscal 2025 was $28.33M, a 26.37% decline from fiscal 2024.
- AbCellera Biologics Inc. investment income, interest for fiscal 2024 was $38.47M, a 8.93% decline from fiscal 2023.
- AbCellera Biologics Inc. investment income, interest for fiscal 2023 was $42.25M, a 162.75% increase from fiscal 2022.
- AbCellera Biologics Inc. investment income, interest for fiscal 2022 was $16.08M, a 382.85% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 3 month as first filed | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $3.64M 10-Q · filed 2026-05-11 | $9.56M derived: sum of 2 quarters · filed 2026-05-11 | $16.33M derived: sum of 3 quarters · filed 2026-05-11 | $23.92M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2025-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $12.69M derived: sum of 2 quarters · filed 2026-02-24 | $20.28M derived: sum of 3 quarters · filed 2026-02-24 | $28.33M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $6.76M 10-Q · filed 2025-11-06 | $14.36M derived: sum of 2 quarters · filed 2025-11-06 | $22.41M 10-Q · filed 2025-11-06 | $28.55M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2025-06-30 | $7.59M 10-Q · filed 2025-08-07 | $15.64M 10-Q · filed 2025-08-07 | $21.78M derived: sum of 3 quarters · filed 2026-05-11 | $31.39M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2025-03-31 | $5.52M 10-Q · filed 2026-05-11 | $8.05M 10-Q · filed 2025-05-08 | $14.19M derived: sum of 2 quarters · filed 2026-05-11 | $23.79M derived: sum of 3 quarters · filed 2026-05-11 | $33.59M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $18.27M derived: sum of 2 quarters · filed 2026-02-24 | $28.07M derived: sum of 3 quarters · filed 2026-02-24 | $38.47M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $9.60M 10-Q · filed 2025-11-06 | $19.40M derived: sum of 2 quarters · filed 2025-11-06 | $29.80M 10-Q · filed 2025-11-06 | $40.77M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $9.80M 10-Q · filed 2025-08-07 | $20.20M 10-Q · filed 2025-08-07 | $31.17M derived: sum of 3 quarters · filed 2026-02-24 | $41.91M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $10.40M 10-Q · filed 2025-05-08 | $21.37M derived: sum of 2 quarters · filed 2026-02-24 | $32.11M derived: sum of 3 quarters · filed 2026-02-24 | $42.89M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $21.71M derived: sum of 2 quarters · filed 2026-02-24 | $32.49M derived: sum of 3 quarters · filed 2026-02-24 | $42.25M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $10.74M 10-Q · filed 2024-11-04 | $21.52M derived: sum of 2 quarters · filed 2024-11-04 | $31.28M 10-Q · filed 2024-11-04 | $39.75M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $10.78M 10-Q · filed 2024-08-06 | $20.54M 10-Q · filed 2024-08-06 | $29.01M derived: sum of 3 quarters · filed 2025-02-27 | $34.56M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $9.76M 10-Q · filed 2024-05-07 | $18.23M derived: sum of 2 quarters · filed 2025-02-27 | $23.79M derived: sum of 3 quarters · filed 2025-02-27 | $25.20M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.03M derived: sum of 2 quarters · filed 2025-02-27 | $15.44M derived: sum of 3 quarters · filed 2025-02-27 | $16.08M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $5.56M 10-Q · filed 2023-11-02 | $6.97M derived: sum of 2 quarters · filed 2023-11-02 | $7.61M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $1.41M 10-Q · filed 2023-08-03 | $2.08M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $665.00K 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $3.33M 10-K · filed 2024-02-20 | ||||
| 2020-12-31 | $293.00K 10-K · filed 2023-02-21 | ||||
| 2019-12-31 | $155.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |